China
China plant-based protein player Starfield raises $100m
Primavera Capital Group has led a USD 100m Series B for Starfield, a Chinese producer of plant-based meats.
China sustainability start-up Bluepha raises $235m
Bluepha, a China-based synthetic biology company working on a range of biodegradable plastics, has raised a three-tranche Series B of CNY 1.5bn (USD 235m).
Goldman, Sofina lead Series C for China CDMO Zhenge
Goldman Sachs Asset Management and Sofina have led a USD 100m Series C round for Zhenge Biotech, a Shanghai-based contract development and manufacturing organisation (CDMO).
Fund focus: Eastern Bell targets digitalisation
As a supply chain specialist, Eastern Bell Capital claims to have a differentiated take on China industrial digitalisation. It has USD 800m in dry powder to prove this thesis
FountainVest buys China QSR restaurant operator from EQT
FountainVest Partners has acquired China F&B Group (CFB), one of the master franchise operators for Papa John’s and Dairy Queen in mainland China, from EQT for an undisclosed sum.
China gene therapy start-up Cure Genetics raises $60m
Advantech Capital has led a USD 60m Series B for Suzhou-based biotech player Cure Genetics. Other investors include Oriza Holdings, Blue Ocean Private Equity, and Qiming Venture Partners.
Singapore's Virtue Diagnostics closes $100m Series B
Singapore-based Virtue Diagnostics, a clinical testing equipment supplier for China and developing markets, has raised a USD 100m Series B round led by Sequoia Capital China and Morningside Ventures.
China's Ince raises $700m across two funds
Ince Capital, a Chinese venture capital firm established by J.P. Gan, formerly a managing partner at Qiming Venture Partners, has raised USD 700m for its second fund and for an accompanying vehicle aimed at later-stage opportunities.
China AI gaming company Parametrix raises $100m
Chinese artificial intelligence (AI) gaming company Parametrix.ai has raised a USD 100m Series B round led by Sequoia Capital China. Existing investors 5Y Capital and Gaorong Capital re-upped.
AGIC exits healthcare business Ritedose to Novo Holdings
AGIC Capital, which specializes in cross-border deals along the China-Europe axis, has agreed to sell pharmaceutical manufacturing and packaging business Ritedose Corporation to Novo Holdings.
China CDMO Thousand Oaks raises $240m
Thousand Oaks Biopharmaceuticals, a China-based contract development and manufacturing organization (CDMO), has raised CNY 1.5bn (USD 240m) in funding led by Goldstone Investment - a private equity unit of CITIC Securities - and CDH Investments.
Jafco closes latest Asia VC fund at $130m
Japanese venture capital firm Jafco has closed its latest Asia fund with USD 130m in commitments. It will focus on China, India, and Southeast Asia.
Eastern Bell raises $2b across US dollar, renminbi funds
Eastern Bell Capital has closed its second US dollar-denominated fund and its sixth renminbi-denominated fund with aggregate commitments of more than CNY 13bn (USD 2bn).
China biotech player GenFleet raises $75m
GenFleet Therapeutics, a Chinese biotech developer focused on oncology and immunology, has secured a USD 75m Series C round led by Huagai Capital.
China's SenseTime perseveres with IPO despite blacklisting
Chinese artificial intelligence (AI) technology developer SenseTime has relaunched its IPO on the same terms, albeit excluding US investors, after being placed on another blacklist by the US government.
ADV backs Asia, North America flooring manufacturer
ADV Partners has acquired a significant minority interest in CFL Technologies, a flooring materials business with a presence in multiple locations in the US, China, and Vietnam.
2022 preview: Healthcare
Healthcare’s high-cost, rapidly digitizing profile will persist regardless of how COVID-19 plays out in the coming years. China appears set for consolidation, including in biotech
2022 preview: China sustainability
Green-tech investment, from electric vehicles to renewable energy, is already in the ascendency as China ponders a carbon-neutral future. Momentum is expected to grow in 2022
2022 preview: China fundraising
Investors held fire on commitments to China managers amid uncertainty over regulatory reforms. Industry participants hope the government will provide clarity, but the fear LPs won’t hurry back
2022 preview: Macro & buyout
Will the bullish investment environment persist through 2022? Most Asia-based private equity players expect to remain busy, although they acknowledge a lack of visibility around macro and geopolitical risk
2022 preview: SaaS
Software-as-a-service continues to benefit from a digitalization push across multiple markets. Investors are looking for differentiation in a market characterized by high valuations and intense competition
China supermarket chain T11 raises $100m
T11, a China-based, technology-enabled supermarket chain, has raised a $100 million Series B led by Alibaba Group. Other investors include Redview Capital and MSA Capital.
Q&A: Legend Capital's Richard Li
Richard Li, president of Legend Capital, on evolving US-China relations, the logic behind the recent wave of regulation, investing in line with government policy, and why LPs should get used to onshore exits
2021 in review: Boom time
Cheap debt and a desire for assets that deliver technology-driven growth have propelled Asia private equity investment to new highs and supported a resurgence in exits. But fundraising still fails to convince